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Summary 
To be recognized by CD8 + T lymphocytes, target cells must process and present peptide antigens 
in the context of major histocompatibility complex (MHC) class I molecule~ The nonimmunogenic, 
low class I-expressing, methylcholanthrene  (MCA)-induced routine sarcoma cell line, MCA 101, 
is a poor presenter of endogenously generated viral antigens to specific CD8 + T lymphocytes 
and cannot be used to generate tumor infiltrating lymphocytes (TIL). Since interferon "y (IFN-3') 
has been shown to upregulate three sets of molecules important for antigen processing and 
presentation, we retrovirally transduced wild-type MCA 101 (101.WT) tumor with the mIFN-'y 
eDNA to create the 101.NAT cell line. Unlike 101.WT, some clones of retrovirally transduced 
101.NAT tumor expressed high levels of class I, and could be used to generate CD8 + TIL. More 
importantly, these TIL were therapeutic in vivo against established pulmonary metastases from 
the wild-type tumor. Although not uniformly cytotoxic amongst several separate cultures, these 
TIL did specifically release cytokines (IFN-3, and tumor necrosis factor-c  0 in response to 101.WT 
targets. 101.WT's antigen'presentation ddidt was also reversed by gene modification with mIFN-3, 
eDNA. 101.NAT had a greatly improved capacity to present viral antigens to CD8 + cytotoxic 
T  lymphocytes. These findings show that a nonimmunogenic tumor, incapable of generating 
a CD8 + T cell immune response,  could be gene-modified to generate a therapeutically useful 
immune response against the wild-type tumor. This strategy may be useful in developing treatments 
for tumor histologies not thought to be susceptible to T  cell-based immunotherapy. 
S 
ome tumor cells  in  mouse and  humans present  pep- 
tide/MHC class I  complexes recognizable by T  cells. 
CD8 + CTL can be generated that specifically lyse human 
and murine tumor cells in vitro and can eliminate established 
tumor in vivo (1-12).  Many tumors, however, are thought 
to be nonimmunogenic (3,  I3). Although there are many 
possible explanations for nonimmunogenicity,  it has recently 
been demonstrated that a nonimmunogenic murine tumor 
poorly presented endogenously generated viral antigens in 
the context of MHC class I, despite the intracellular pres- 
ence of these antigens in high quantities (14). Furthermore, 
in a mutant lymphoma cell line with a known antigen pre- 
sentation defect, tumor antigens were not presented, while 
in its parent, nonmutated line they were (15). These findings 
suggested that a tumor might evade recognition by CD8 + 
T  cells by failing to present tumor antigens that were not 
absent, as Hewitt et al. hypothesized (13), but that were in- 
stead hidden intracelhlarly, and not presented on the cell 
surface. 
Our understanding  of the molecular mechanisms that might 
be involved in the evasion of recognition by CD8 + T cells 
has  grown  significantly over  the  past  several years. The 
specificity of T cell recognition of a cognate partner cell occurs 
via the interaction of the TCR with a MHC molecule to 
which a peptide is bound. Some peptide/MHC complexes 
that are designated antigenic trigger a T cell response that 
can consist of proliferation, upregulation of surface molecules, 
activation of lytic machinery, and/or secretion of cytokines. 
The peptides presented by class I molecules are usually frag- 
ments of endogenous proteins that are cleaved, frequently 
to an ultimate size of eight or nine amino acids (16-20).  This 
task is possibly achieved, in part, by a molecular complex 
known as the proteasome (21, 22). Peptide fragments may 
be transported across the membrane of the endoplasmic retic- 
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proteins, related to the products of the mnlti-drug resistance 
genes, designated TAP 1 and 2 (23-26).  Both the putative 
peptide transporter proteins and the proteasome component 
molecules appear to be very closely associated with the MHC 
region on chromosome 17 in the mouse, or on chromosome 
6 in the human (21-26). Thus, there may be an antigen pre- 
sentation kit consisting of the three groups of molecules ap- 
parently required for endogenous antigen presentation: pro- 
teasome,  peptide  transporter,  and  class  I  H  chain  with 
B2-microglobulin.  It is significant that the known compo- 
nents of this equivalent of a eukaryotic operon for antigen 
presentation  are all upregnlatable by IFN-3r (27). 
In the experiments reported here, we set out to study the 
effects of insertion of the cDNA for mlFN-7 on antigen pro- 
cessing and on presentation  in a tumor.  The nonimmuno- 
genic murine methylcholanthrene (MCA)-induced sarcoma, 
MCA 101, has a very poor ability to present endogenously 
generated viral antigens (14). This tumor grows rapidly and 
lethally in nonimmunosuppressed hosts (3, 8). Furthermore, 
of seven MCA-induced tumors generated and characterized 
extensively in our laboratory (3, 6, 7, 8, 14, 28), only MCA 
101 can neither act as an immunogen in vivo nor generate 
CTL in vitro (3, 8). In the current studies, we retrovirally 
transduced these cells with the cDNA coding for mlFN-% 
Our aim was not to use IFN-7 in these experiments for its 
effects on the immune system, but instead, for its effects on 
the antigen presentation capabilities  of a tumor cell. We show 
that  MCA  101 can be converted from a poor presenter of 
endogenously  generated  antigens  to  a  tumor  capable  of 
efficiently presenting antigens. Furthermore, this conversion 
is correlated with a change in the tumor's  ability to elicit 
tumor inf~trating lymphocyte (TIL) cells. Whereas wild-type 
tumor does not elicit TILL cells, tumor retrovirally transduced 
with the cDNA for IFN-7 does. Most importantly,  these 
TIL are active against the low class I-expressing wild-type 
MCA 101. These experiments represent the first reported to 
use functional assays to study the antigen presentation capa- 
bilities of a tumor before and after gene modification,  and 
correlate this modification with in vivo behavior. 
Materiah and Methods 
Tumor and Animals.  MCA-induced sarcomas (101 and 102) (3) 
were generated in our laboratory in 8-wk-old female C57BL/6n 
(B6) mice (Animal Production Colonies, Frederick Cancer Research 
and Development Futility, National Institutes of Health, Frederick, 
MD) by intramuscular injection of 0.1 ml of 0.1% 3-MCA in se- 
same seed oil. Tmnor lines were passaged in 136 mice, and all tumors 
were of early transplantation  passage (passage 3-7). Tumors were 
harvested from mice, triph-enzyme digested with 0.1% collagenase, 
i Abbreviations used in this ~t,er: CM, complete  medium; ER., endoplasmic 
reticulum; LAK, lymphokine-activated  killer cells; MCA, methylcholan- 
threne; MCN, mean channel number; Nco K, neomycin  resistance; NP, 
nudeoprotein; PKS, wild-type  influenza virus A/PK/8/34; TATA, tumor- 
associated transplantation antigen; TIL, tumor-infaltrating lymphocytes; 
Vac, vaccina virus; WT, wild-type. 
0.002% DNase, and 0.01% hyaluronidase (all from Sigma Chem- 
ical Co., St. Louis, MO), and maintained in monolayer culture in 
complete  medium  (CM)  containing  RPMI  1640, 10%  heat- 
inactivated FCS, 0.1 mM nonessential amino acids, 1.0 mM so- 
dium pyrnvate (all from Biofhids Inc., Roekville, MD), 5  x  10-s 
M 2-ME (Aldrich Chemical Co., Milwaukee, WI), and 0.03% (100 
raM)  glutamine  (National  Institutes  of Health  Media  Unit, 
Bethesda, MD). 
Retmuiral Transduction of Turaor Lines.  A long-term cultured line 
of MCA 101, was cloned by limiting  dilution  techniques. All 41 
clones tested expressed low levels of class I. One of these clones 
was designated 101.WT and was plated at 10  ~ cells in CM in a 75- 
cm  2 tissue culture flask (Falcon; Becton Dickinson Labware, Ox- 
nard,  CA) and allowed to adhere overnight.  To create the bulk- 
transduced  cell line  101.NAT, viral supernatants  were added to 
washed adherent 101.WT tumor cells in the presence of polybrene 
(8 #g/ml) for 12 h at 37~  as described previously (29). CM was 
added the next morning.  The retroviral construct used was ob- 
tained from E. Gilboa (Memorial Sloan-Kettering Cancer Center, 
New York, NY) and has been described previously under the desig- 
nation  DC/TKIFN~  (30), but which was also referred  to as 
NAT/IFN-~/by the Gilboa group, and is simply called NAT in this 
manuscript.  Briefly, the construct was derived from the genome 
of the Moloney murine leukemia virus and contained the mlFN-~/ 
gene, which was under the transcriptional  control of the tbymi- 
dine kinase promoter,  and the neomycin resistance geue (Neo IL) 
gene, which was under the transcriptional control of the LTR from 
the Moloney murine leukemia virus. The bulk-transduced cell line 
101.NAT was  cloned  and  two  high  class I-expressing  clones 
(101.22H and  101.28H), and two low class I-expressing  clones 
(101.18L and 101.25L) were selected for further work. A bulk con- 
trol cell line transduced  with the Neo K  gene alone and called 
101.LXSN was generated in the same way, eacept that the retrovirus 
used was designated LXSN. This virus is the Moloney murine 
leukemia virus backbone with the Neo R gene alone, and was ob- 
tained  from Dr.  D.  Miller  (Fred Hutchinson Cancer  Research 
Center, Seattle, WA). Cells were selected in 1 mg/ml (0.5 mg/ml 
active) G-418 sulfate (Geneticin; Gibco Laboratories, Grand Island, 
NY) for 2 wk and then cloned at 0.2 cells/well. Successful  introduc- 
tion of cDNA was verified by Southern blotting after selection of 
the transduced cells in G-418. mlFN-~ activity in supernates of 
transduced tumor cells was measured by ELISA (Quantlkine; R&D 
Systems, Inc., Minneapolis, MN). 
FACS  ~ Analysis.  Cell surface class I expression was measured 
by FACS  |  analysis using a FACScan  |  440 (Becton Dickinson  & 
Co., Mountain View, CA). Fresh tumors were harvested and triple- 
enzyme digested vide supra before st~ining with appropriate anti- 
bodies for FACS  |  Cultured tumor cell lines were harvested with 
0.02% ~,  washed, then stained for 30 rain with culture su- 
pernatant from the hybridoma 28.8.6s (anti-Kb and Db) (31), ob- 
tained from Dr. D. Sachs (Massachusetts General Hospital, Boston, 
MA), or with the isotype-matched (IgG2a) control antibody (Becton 
Dickinson & Co.) followed by goat anti-mouse FITC-conjugated 
antibody (Boehringer Mannheim Biochemicals, Indianapolis, IN). 
FACS  |  analyses were standardized with Calibtite  flow cytometer 
beads (Becton Dickinson  & Co.). 
Generation of TIL and Anti-viral E.~ector Cells,  TIL were gener- 
ated from tumors that were injected subcutaneously and harvested 
"~2 wk later. They were enzymatically digested as described above, 
then washed twice with HBSS (Biofluids Inc.). Thy 1.2-bearing 
cells within the tumor digest were separated by immunobeading 
using magnetic beads coated with Thy 1.2 antibody and cultured 
in 20 U/ml of rhIL-2 (Cetus Corp., Eme~filh, CA) as previously 
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were generated as described previously (14). Briefly, female 6-wk- 
old B6 mice were primed with 20 hemagglutinin U of PR8 viral 
allantoic  fluid. After at least 2 wk, spleens  were removed, dispersed, 
and cultured in IMDM with 7.5% heat-inactivated FCS (Biofluids 
Inc.). Splenocytes  were then cultured for 7 d in the absence  of IL-2, 
either with synthetic peptide at 1 #g/ml ('~0.6 #M), or with PR8- 
infected spleen cells (14). 
In Vivo Tumor Therapy Experiments.  8-12-wk-old  C57BL/6n 
mice were irradiated with 500 tad and then injected intravenously 
with 3  x  106 wild-type MCA 101, 101.22H, or 101.28H (high 
class I-expressing clones of the mlFN-3, gene-modified cell line 
101.NAT) tumor cells in  1 ml of HRSS to induce pulmonary 
metastases. On day 3, TIL were injected at doses specified  in the 
text. Where six'dried, mice were treated intraperitoneally with 
10,000 U rlL-2 in 0.5 ml HBSS twice daily for five consecutive 
days. On day 14, after tumor injection, all mice were ear tagged, 
randomized, and killed. Pulmonary metastases were enumerated 
in a coded, blinded fashion as described previously (3). If pulmo- 
nary metastases e~eeded 250, they were deemed too numerous to 
count (TNTC). 
Viruses and Infection of Tumor Lines.  3  x  106 tumor cells were 
washed three times in RPMI 1640, then placed in 1 ml of RPMI 
with 0.1% BSA (Sigma  Chemical  Co.), and 30 mM Hepes (Biofluids 
Inc.) at pH 6.8. Cells were then infected for 90 min at 37~  with 
20 PFU/cell of recombinant vaccinia virus constructs containing 
either the influenza A/PR/8/34 nucleoprotein (NP) gene, or a 
non-cross-reactive control gene, neuraminidase (NA) (32). After 
infection, target cells were incubated in CM for 3 h at 37~  then 
labeled with SlCr as described below. The production of the viral 
antigens, as a measure of infection by vaccinia, was quantified by 
FACS  |  with  the  antivaccinia mAb  designated TWII,  kindly 
provided by Drs. J. Yewdell  and J. Bennink (National Institute of 
Allergy and Infectious Diseases, Bethesda, MD), followed  by goat 
anti-mouse FITC-labeled antibody (GAMF) (Becton Dickinson & 
Co.). Cell membranes were rendered permeable by fixation with 
0.5% paraformaldebyde  for 20 rain at room temperature, stained 
with TWII mAb in the presence of 0.1% saponin (Sigma Chem- 
ical Co.) in PBS, then stained with FITC-labeled goat anti-mouse 
antibody as a second reagent as described previously (14). 
51  51  Cr Release Assays and Cytokine Release Assays.  4 h-  Cr re- 
lease assays  were performed as described previously (6). Briefly, 2 
x  106 tumor targets in 0.5 ml of CM were labded with 200 #Ci 
of SlCr (New England Nuclear, Boston, MA) for 90 min.  For 
studies of endogenous presentation, cells were infected with virus 
before SlCr labeling as detailed above. Labeled tumor cells were 
coincubated with antiviral effector CTL lines or TIL for 4 h. Su- 
peruatants were harvested  and counted with a gamma counter (LKB 
Instruments, Inc., Gaithersburg, ME)). Percent lysis  was calculated 
as follows: 100 x [(experimental  cpm -  spontaneous cpm)/(max- 
imal cpm  -  spontaneous cpm)]. Effector recognition of tumor 
targets by measuring cytokine release was done using tumors as 
described pz~iously (7). Briefly, 5  x  10  s effector ceils were in- 
cubated with 106 stimulator ceils for a period of 18-24 h in 24- 
well tissue culture plates. Supernatants were then harvested and 
assayed for cytokine production. 
Results 
Transfection of  MCA 10I with mlFN-  T.  We have recently 
demonstrated that a routine MCA-induced sarcoma, MCA 
101, was a poor presenter of endogenously generated viral 
antigens in the context of MHC class I molecules to CD8 + 
CTL. This defect was found to be reversed by incubation 
with exogenous mIFN-7 (14). The question remained as to 
whether MCA 101 was nonimmunogenic because it lacked 
tumor-associated transplantation antigens (TSTA), or because 
of its failure to present some postulated, but as yet unidentified, 
TSTA. 
Since the amelioration of MCA 101's ability to present en- 
dogenous antigens after treatment in vitro with exogenous 
mIFN-3, was transient, and correlated with the duration of 
class I expression (data not shown), we hypothesized that 
retroviral transduction of MCA  101  with the cDNA  for 
mIFN-3, would have a prolonged effect on the processing 
and presentation of endogenous antigen by virtue of the stable 
insertion of the gene. Thus, a Moloney leukemia retroviral 
construct, designated NAT, containing both the mIFNw gene 
and the Neo R  gene was used. Bulk MCA 101 was cloned 
by limiting dilution to generate 41 different clones, all of which 
expressed low quantities (mean channel number [MCN] <10) 
of surface MHC class I molecules. We then retroviraUy trans- 
duced one of these wild-type dones, designated 101.WT, with 
the cDNA for mlFN-3,, and selected it in G-418 for 2 wk 
to create the cell line designated 101.NAT. In parallel, 101.WT 
was transduced with a Moloney leukemia virus vector, desig- 
nated LXSN, containing the Neo R gene without the IFN-3, 
gene, to create the cell line 101.LXSN, which was treated 
in exactly the same way in all respects as 101.NAT. Although 
the bulk-transduced tumor line 101.NAT  secreted levels of 
mlFN-3, that were consistently <5 U/106 cells per 24 h, as 
measured by ELISA, it did express much higher levels of sur- 
face class I molecules as measured by FACS  |  analysis than 
the Neo R bulk-transduced  cells 101.LXSN and 101.WT (Fig. 
1). This pattern of  very low or unmeasurable mlFN-3, produc- 
tion with greatly increased class I production is not dissimilar 
to that seen by Gansbacher et al. (30).  As shown in Fig.  1, 
increased class I expression was seen in both fresh and cul- 
tured tumor lines. 101.WT and 101.LXSN showed two popu- 
lations of cells in fresh preparations. These data were inter- 
preted to indicate that the lower class I expressing cells in 
these preparations were tumor cells and that the higher class-I 
expressing cells were likely to be infdtrating T cells and stromal 
cells. Extensive immunohistochemical studies of subcutaneous 
nodules, as well as pulmonary metastases of MCA 101, have 
been done using the same antibody as was used for FACS  | 
analysis (28.8.6s). In these studies, MCA 101 tumor cells were 
found to retain their low expression of class I molecules in 
vivo (Dr. Jeffrey S. Weber, National Cancer Institute, Bethesda, 
MD, personal communication). Expression of  the Neo R gene 
was evidenced by selection of the transduced cell line in 1 
mg/ml of G418.  Tumor cells that did not receive the Neo 
R  gene could not be grown in G418 (data not shown). In- 
tegration of the Neo R gene was shown by Southern transfer 
at 3 mos after transduction (not shown). 
Presentation of Viral Antigens by mIFN-y Gene-modified  MCA 
I01 to Antiviral CTL.  In an effort to test the effect of IFN-'y 
gene transduction on the ability of MCA 101 to present en- 
dogenous antigens,  we infected IOI.WT,  IO1.LXSN,  and 
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Figure 1.  FACS  ~ profiles of the following  three bulk tumor cell lines: 
101.WT (wild-type  MCA 101), 101.LXSN (MCA 101 transduced  with 
the Neo R gene alone), which was made from a done of 101.WT, and 
101.NAT (MCA 101 transduced  with the Neo K gene and with IFN-'y), 
which was also made  from the same  clone  of 101.WT as 101.LXSN. Profiles: 
(left) cultured tumor lines; (right) fresh tumor preparations, which have 
been harvested  from  subcutaneous  sites  in mice  and triple  enzyme-digested 
as described  in Materials  and Methods.  Visible  in the profiles of the fresh 
preparations is a bimodal curve (top). The high-expressing  cells in these 
curves probably represent stromal cells along with infiltrating  host im- 
mune cells. 
101.NAT with wild-type influenza A/PR/8/34 (PR 8), then 
subjected them to killing by appropriately directed CTL. Gene- 
modified 101.NAT  was killed more efficiently in this assay 
(25% at an E/T of 30:1) than were 101.WT and 10LLXSN 
(<5% at an E/T of 30:1). However, FACS  |  data showed poor 
infection of 101.NAT compared with the other two cell lines 
(data not shown), suggesting that the endogenous mlFN-'y 
gene made these tumor cells less susceptible  to infection by 
the PR8 virus. This observation is consistent with the ob- 
served suppressive effect of exogenous IFN-3: on viral infec- 
tion with influenza A  (33). 
To overcome this problem, we repeated our experiments 
using  vaccinia  viruses  genetically engineered  to  contain 
influenza A  genes. Effector cells were splenocytes from B6 
mice stimulated in vivo with Vac-NP and in vitro with the 
NP peptide (amino acids 365-380)  (34,  35).  As  shown in 
Fig. 2, wild-type MCA 101 (101.WT)  was not killed when 
it was sham infected (no virus, NV), when it was infected 
with the control vaccinia virus containing the NA gene, or 
when it was infected with the vaccinia virus engineered to 
express the influenza A NP gene. IFN-3/gene-modified tumor 
cells (101.NAT) were also not killed when sham infected (NV) 
or when infected with a control virus (Vac-NA),  but were 
specifically killed when they were infected with the Vac-NP 
virus. Like 101.WT, 101.LXSN  (not shown) did not present 
viral antigens, indicating that the improvement in 101.NAT's 
ability to present antigen was not due simply to the effects 
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Figure 2.  s~Cr  release  assay  in which  wild-tyl~  101.WT, (left), or IFN-3' 
gene-modified  101.NAT, (righ  0, are subjected to killing  by CTL directed 
against the influenza  A NP gene  product. Cells  were  either sham  infected 
(NV), infected  with an engineered  vaccinia  virus containing  the influenza 
A hemagglutinin  gene as a control (Cont Vat), or infected  with an en- 
gineered  vaccinia  virus containing  the influenza  A nucleoprotein  gene (NP 
l-tic). Only the mlFN-'), gene-modified  MCA 101 tumor infected  with 
the appropriate virus was killed in this assay. This finding  demonstrates 
that the modification  of MCA 101 with the gene for IFN-3' abrogates 
its inability  to present endogenous  antigen. 
of retroviral transduction. It thus appeared that by inserting 
the mlFN-3~ gene into a bulk population of MCA 101, we 
could convert it from a poor presenter of antigen to a cell 
line capable of presenting antigen to a similar extent as our 
most immunogenic tumors (see reference  14). This finding 
led us to hypothesize that MCA 101 might be capable  of 
presenting its own tumor antigens in vivo. 
Generation  of TIL  from  mlFN-'y  Gene-modified  MCA 
101.  Generation of successful cultures of TIL from wild- 
type MCA 101 has never been achieved in our laboratory. 
To test whether the done being used in the present studies 
was similar to the parental line, tumors were implanted sub- 
cutaneously in syngeneic B6 mice, and 10-20 d later TIL were 
harvested.  Two of two blind attempts at the establishment 
of TIL cultures  from wild-type MCA  101  (101.WT)  or 
MCA 101 transduced with the Neo R gene alone (101.LXSN) 
yidded no successful TIL cultures. Although bulk-transduced 
101.NAT tumor at first appeared to be successful, in two of 
two blind attempts the TIL cultures were ultimately over- 
grown with tumor. We hypothesized that some low class 
/-expressing tumor clonotypes, which may be the rare cells 
visible in Fig. 1, existed in the bulk population, and that they 
were able to overgrow the culture before TIL could be estab- 
lished. 
To obtain pure cultures of uniformly high class I-expressing 
transductants, the bulk-transfected MCA 101 (101.NAT) was 
cloned. We found that the insertion of the cDNA for IFN-'y 
caused increased expression  of steady-state  surface class I as 
measured by FACS  ~ analysis on some, but not all, of the tumor 
clones tested (Fig. 3). Two high (H) class 1--expressing clones, 
101.22H  and 101.28H,  and two low (L) class I-expressing 
clones  101.18L and  101.25L,  were  selected  from  bulk- 
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Figure 3.  Neither the bulk-transduced tumor, nor any of the clones 
from the bulk-transduced  101.NAT produced  measurable  levels of IFN--y 
by ELLS&  However,  bnlk-transduced  cells  using  the IFNw vector  exFessed 
much higher levels of surface class I than those calls transduced  with a 
control vector  expressing only  the Neo IL gene. FACS  |  profihs of two 
cell lines  cloned  from  the bulk-transduced  MCA 101 tumor after  selection 
in G418. With a MCN of  8, done 18L was among  those  clones  ~pressing 
the lowest levels of class I after staining  with the mAb 28.8.6s (which 
stains both K  b and Db). FITC labeled  goat anti-mouse  Ab was used as 
a second reagent. C]one 22H, on the other hand, was among  the highest 
class I expressers  with a MCN of  882. The experiment  shown  was repeated 
twice  with similar  results  over  a period  of several weeks, showing  stability 
of the phenotype. 
transduced 101.NAT. Despite their variable levels of class I 
expression, none of these clones secreted  >5 U  of mIFN- 
3,/106 ceUs/ml per 24-h ELISA. These clones were then im- 
planted subcutaneously into syngeneic B6 mice. There were 
no significant differences between the growth rates of high- 
and low-dass-I expressing tumors in vivo (data not shown). 
When subcutaneous tumors were harvested after 10-20  d, 
Thy 1.2 + cells were obtained by immunobeading of single 
cell suspensions of tumor cells. In two of two blind attempts, 
we could not grow TIL from low class I-expressing tumor 
clones  (101.18L or  101.25L)  of the  mIFN-'y-transduced 
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Figure 4.  In this experiment, tumor was injected on day 0 to create 
lung metastases.  On day 3, mice  received  one of several treatments  listed. 
On day 14, the number of pulmonary  metastases were enumerated  and 
are ex~essed. CD8 + TILL  generated  from a high class I-~=pressing  mlFN- 
-y-transduced  tumor  clone (101.221-1)  are effective  not only  against  the gene- 
modified tumor, but against the wild-type tumor (101.WT) as well 
101.NAT. On the other hand, in six of six attempts, we could 
consistently grow TIL from high class I-expressing tumor 
clones of mIFN-'y-modified 101.NAT. Like other routine TIL 
generated in our laboratory, the TIL cultures used in vivo 
in Fig.  4  were found to be exclusively  CD8 + by FACS  | 
(data not shown). These antitumor CTL were then expanded 
in vitro in 20 U/ml of rhII.,2 and tested in vivo and in vitro. 
In Vivo Effectiveness of TIL Generated  from ralFN-7 Gene- 
modified MCA  101.  In an effort to test whether the TIL 
generated from high class I-expressing mIFN-3,-transduced 
clones could be active in an adoptive immunotherapy model 
against established  wild-type tumor in vivo, we used a 3-d 
lung metastases model (3). In these experiments (Fig. 4), mice 
were injected intravenously with fresh 101.WT or 101.22H 
tumor ceils. On day 3, mice were treated with either saline 
alone,  IL-2 (10,000  U) in saline twice daily for 5 d, or the 
same dosage of IL-2 plus varying dosages of TIL. Mice were 
kilhd on day 14 when their lungs were harvested and counted 
in a blind fashion for the number of  pulmonary tumor nodules. 
As shown in Fig. 4, TIL generated from the mlFN-3~ gene- 
modified 101.22H  tumor were effective against pulmonary 
metastases from the 101.22H tumor. Most significant, how- 
ever, was the effectiveness of these CD8 + TIL against the 
wild-type MCA 101 tumor. In the experiment shown, the 
average number of pulmonary metastases from 101.WT were 
reduced from 200 in the Ib2 alone group to 48,  8,  and 0 
at 106 TIL, 3  x  106, and 107 TIL, respectively. TIL gener- 
ated from mlFN-~/gene-modified, high class I-expressing 
tumor done 101.22H  were therapeutically effective against 
the unmodified tumor in three other repeats of the same ex- 
periment. 
Specificity of Anti-MCA I01 TIL In Vitr~  Four SlCr re- 
lease  assays were  performed on  the  TIL  generated  from 
101.22H tumor. Only two of four T1L cultures obtained from 
mIFN-'y gene-modified tumor were specifically cytotoxic. 
However, the two cultures that were cytotoxic demonstrated 
relative tumor spedfidty (Fig. 5). Two TIL cultures that were 
not lytic against fresh tumor preparations in vitro were still 
therapeutic in vivo. This finding was consistent with previous 
data (9) that showed that CD8 + TIL that were therapeutic 
in vivo were not in every case cytotoxic. 
TIL generated from IFN-'y-modified tumor were treated 
for release of cytokines after coincubation with appropriate 
tumor ceils. TIL derived from 101.22H  tumor were tested 
by exposure to a variety of stimuli. The results shown in Fig. 
6 made use of the same cells as were used one day earlier 
in the therapy experiment depicted in Fig. 4. Maximal re- 
lease was gauged when TIL were stimulated with an anti- 
CD3 antibody, 2Cll. Background levels of  TNF-ot and IFN-'y 
when TIL were incubated alone (without stimulation) were 
relatively low for both cytokines (Fig. 6). Fresh tumor prepa- 
rations  alone were  found to  secrete  <(5  U  of IFN-3,/106 
cells/m1 per 24 h, with the exception of 101.22H which pro- 
duced 6.3 U  IFN-'y/106 cdls/ml per 24  h.  Production of 
TNF was variable by fresh tumor preparations, but was uni- 
formly <20 U/106 cells/m1 per 24 h. Values obtained from 
tumor alone were subtracted from values obtained from tumor 
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Figure 5.  To determine whether the TIL generated from the mlFN-~/ 
gene-mMitied MCA 101 tumor (101.22II) were tumor specific, a 4-h 51Cr 
release assay  was done using a variety of targets including  wild-type MCA 
101  (101.WT),  101.WT after  a 48-h pretreatment  with 200 U/ml of 
nnlFNw (101.WT + Exogenous 3,), IFN-3, gene-modified  MCA 101 done 
22H, which is a high expresser of class I (101.22H), or a control tumor, 
MCA 102 (102.WT) treated exactly as was MCA 101. As an additional 
control, we included a clone of MCA 101 (101.18L), which is IFN-3' gene 
modified in the same way as was done 101.22H, but which expresses low 
levels of class I. 101.WT  +  Exogenous 3' and 101.22H were lysed rela- 
tively more dficiently than controls. This finding indicates that tumor- 
associated antigen is being  recognized which is rehtively specific  for 101.WT, 
and which requires relatively high class I expression for killing in a 4-h 
slCr release assay. 
plus  TIL.  The most important finding was that  101.WT 
stimulated release of IFN-% as well as t01.22H,  and release 
of TNF-o~ was almost as great when stimulated with 101.WT 
as with 101.22H. 102.WT, another MCA-induced sarcoma, 
was prepared in exactly the same way and used as a control. 
The primary purpose of this control was to see whether the 
cytokine rdease for the 101 tumor was specific.  Control tumor 
102.WT  stimulated  substantially less cytokine release from 
these TIL than did 101.WT or 101.22H. These results indi- 
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Figure 6.  TILL  generated from 101.22H were tested for the capacity to 
release TNF and IFN~ to the tumor stimulators listed. 2Cll mAb (anti- 
CD3) was used to test maximal release, and CTL alone (None) was used 
to test spontaneous release. This graph shows that 101.WT stimulated TIL 
to release r  (mlFN-qr and mTNF-~) nearly as well as its mIFN-3, 
gene-modif~  counterpart 101.22H. As in the case of the cytotoxicity assay 
depicted in Fig. 5, these TIL were found to be relatively, but not abso- 
lutdy specific  (note some release of cytokines against the 102.WT tumor). 
cared significant specificity in the response and furthermore 
suggested a possible mechanism for the action of the TIL 
cells in vivo. These experiments were repeated with high class 
I-expressing,  transduced tumor clone 101.28H with similar 
results. Thus, TIL generated from mIFN-% gene-modified 
tumor clones could be triggered to secrete, in a relatively 
tumor-specific fashion, IFN-qr and TNF-oe against not only 
high class I-expressing  tumor clones, but also against  the 
low class I expressing-wild-type tumor. 
Discussion 
A major problem with cellular immunotherapies of cancer 
in humans has been the limited ability to generate therapeutic 
cells with antitumor properties in vivo. A recent approach 
to this problem has been to exploit the immunomodulatory 
effects of genetic modification of tumor cells with cytokine 
genes, including the IFN-3, gene (30, 36-38). The MCA 101 
murine sarcoma may be a model for many tumor histologies 
because it has no demonstrable immunogenicity (3, 14). We 
show here that retroviral-mediated transduction of wild-type 
MCA 101 with mlFN-~/cDNA enables the generation of 
CD8 + TIL, which cannot be generated from the wild-type 
tumor. Most importantly, these TIL were therapeutically  active 
in vivo against both the gene-modified and the wild-type 
tumor in a 3-d lung metastases  model. Although the 101.WT 
tumor was not consistently lysed by therapeutic TIL, it did 
stimulate the release of  cytokines with relative specificity. Fi- 
nally, mlFN-3, gene-modified  MCA 101 tumor presented viral 
antigens much more efficiently than controls,  suggesting a 
mechanism for these observations. 
Although mlFN-qr transduced-tumor lines and clones se- 
crete little, if any, mlFN-3, into culture supematant, the effect 
of the cytokine could act primarily via intracdlular IFN-3' 
receptors. Based on our experiments that show steady state 
increases in the expression of cell surface-dass I molecules, 
and on the enhanced killing by CD8 + T cells in experiments 
using a defined antigenic system, we may infer that there is 
increased density of tumor antigen peptide/class I molecule 
complexes on the cell surface. This inference is strengthened 
by recent evidence which shows that antigen presentation 
may be enhanced at several  important points by the mlFN-'y 
molecule. In addition to increasing class I H chain at the level 
of transcription  initiation (39), IFN-3, has also been shown 
to increase steady state levels of TAP 1 and 2, the putative 
peptide transport proteins, as well as the gene products similar 
to the low-molecular mass polypeptide (LMP) or proteasome, 
which may be involved in cleaving proteins into peptides be- 
fore feeding them into the EK or post-EK compartment where 
they bind to class I molecules (27). Finally, IFN-3, has been 
shown to be a potent upregulator of certain accessory mole- 
cules, ICAM-1 among them (40), and while not specifically 
addressed in the studies presented here, the effect of IFN-3, 
on these molecules may play an important role in the phe- 
nomena described here. The relative contributions of these 
mechanisms are currently being addressed in our laboratory. 
Increased antigen density on mlFN-~, gene-modified MCA 
101 may explain why a therapeutically useful CD8 + T cell 
1428  Enhancement of Antigen Presentation  of Nonimmunogenic Tumor response can be obtained from high class I-expressing clones, 
and not  from low class  I-expressing mlFN-3(  transduced 
clones, control Neo R-transduced clones, or from wild-type 
tumor. There is evidence in tumor immunology that an im- 
munologically strong afferent tumor stimulus can elicit a re- 
sponse  against  an immunologically much weaker efferent 
stimulus  (41).  Alternatively,  IFN-'y  could  act  primarily 
through upregulation of class II expression on macrophages 
and dendritic cells, thereby enhancing antigen presentation 
to Th cells (42). 
During tumorigenesis, tumors that poorly present endog- 
enous antigens might enjoy a selective advantage since muta- 
tions of normal cell proteins and expression of oncogene prod- 
ucts may yield antigenic peptides that could result in the lysis 
of the incipient cancer. It has recently been demonstrated that 
viruses can persist in neurons because they lack class I expres- 
sion (43). However, the related concept that tumor cells can 
escape immunosurveillance by T cells of tumor cells is con- 
troversial, and the role of class I molecules in this process 
is unclear (44). In fact, there is evidence that absence of class 
I makes some tumors more susceptible to lysis by NK cells 
(45). Nevertheless, MCA 101 is an extremely virulent tumor 
that  may have benefited during its  genesis from its  poor 
antigen-presenting abilities  (14). The explanation of MCA 
101's poor capability to present endogenous antigen, which 
appears to be entirely reversible with IFN-% may stem from 
its possession of a gene product not unlike the E1A protein 
of the adenovirus (46), as has been suggested for small cell 
lung cancer (47). It is in fact known from other studies, that 
MCA 101 suppresses  class I production at the level of tran- 
scription initiation (48). 
Our findings may have strategic implications for the de- 
velopment of immunotherapies for cancer in humans. A can- 
didate for this approach may be a human tumor that fails 
to present endogenously synthesized antigen because it has 
decreased class I synthesis and normal class I transport, which 
can be upregulated by treatment with hlFN-% This tumor 
could then be used to establish a line in vitro that would 
then be transduced with the gene for IFN-3', subsequently 
reimplanted at a subcutaneous site, and then harvested sev- 
eral weeks later for TIL. Thus far, our studies in this direc- 
tion (N. P. Restifo, unpublished observations) suggest that 
some human tumor histologies, such as small cell lung cancers, 
may have antigen presentation defects very similar to those 
described previously for MCA 101: specifically, those with 
low steady state expression of dass I, but which have normal 
transport (14). Thus, our work with the murine tumor MCA 
101 suggests that human tumor cells previously considered 
to be nonimmunogenic could be rendered better presenters 
of endogenous antigen by IFN-3~ gene modification. This 
approach  may be  useful in  generating  CD8 +  antitumor 
effector T  cells  against  tumor  histologies  not  previously 
thought to be susceptible to T cell-based immunotherapies 
of cancer. 
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